Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Enrique M Ocio, MD, PhD, Pilar Herrera, MD, PhD, Teresa Olave, MD, Salut Brunet, Albert Oriol, Maria-Pilar Martínez-Sánchez, Miguel A. Sanz, MD, PhD, Marta Mateos, MD, Pilar Aliseda, MD, Ivo J. Winiger, MD, Sushant Hardikar, Maria Victoria Mateos, MD, PhD, Javier Lopez, Jesús F. San-Miguel, MD, PhD

Blood (2012) 120 (21): 1512.

https://doi.org/10.1182/blood.V120.21.1512.1512

Published: 2012

Journal Articles

Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Oliver G. Ottmann, MD, PhD, Daniel J. DeAngelo, MD, PhD, Guillermo Garcia-Manero, Michael Lübbert, Anand Jillella, MD, Mikkael A. Sekeres, MD, MS, Anita Zahlten, PhD, Margaret Squier, MD, PhD, Suddhasatta Acharyya, PhD, Ivo J. Winiger, MD, Pierre Fenaux, MD, PhD

Blood (2011) 118 (21): 459.

https://doi.org/10.1182/blood.V118.21.459.459

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD

Blood (2011) 118 (21): 1529.

https://doi.org/10.1182/blood.V118.21.1529.1529

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Richard F. Schlenk, MD, Jürgen Krauter, MD, Markus Schaich, MD, Didier Bouscary, MD, PhD, Hervé Dombret, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Anita Zahlten, PhD, Lu Wang, PhD, Oliver G. Ottmann, MD, PhD

Blood (2011) 118 (21): 423.

https://doi.org/10.1182/blood.V118.21.423.423

Published: 2011

Journal Articles

A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

Jürgen Krauter, MD, Richard F. Schlenk, MD, Markus Schaich, MD, Didier Bouscary, MD, Hervé Dombret, MD, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Bourras-Rezki Bengoudifa, Oliver G. Ottmann, MD

Blood (2010) 116 (21): 3310.

https://doi.org/10.1182/blood.V116.21.3310.3310

Published: 2010

Journal Articles

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Pierre Fenaux, MD, PhD, Daniel J DeAngelo, MD, PhD, Guillermo Garcia-Manero, MD, Michael Lübbert, MD, PhD, Anand P. Jillella, MD, Mikkael A. Sekeres, MD, MS, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Xiaodong Li, PhD, Oliver G. Ottmann, M.D.

Blood (2010) 116 (21): 4957.

https://doi.org/10.1182/blood.V116.21.4957.4957

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only